5439042025-04-012025-06-305439042025-04-012025-06-30in-capmkt:OtherExpenses1Member5439042025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15439042025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25439042025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss35439042025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss45439042025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss15439042025-04-012025-06-30AuditorDomain15439042025-04-012025-06-30AuditorDomain2iso4217:INRiso4217:INRxbrli:shares543904MANKINDNOTLISTEDINE634S01028MANKIND PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312025-07-312025-07-14INRCroresQuarterlyFirst quarterSingle segmentPharmaceuticals2025-07-3114:30:002025-07-3115:50:00Declaration of unmodified opinion2025-04-012025-06-30UnauditedConsolidated3570350000079880000036502300000585680000040497000006294000007834100000170650000021868000008865800000311291000005373200000053732000001109400000-15070000095870000004414500000000317000004446200000-76000004438600000438320000063000000437600000062600000412700000110.6210.60010.6210.6Due to limitation of characters in xbrl utility, we are facing constraints to disclose all notes to accounts. Kindly refer PDF version of financials results uploaded on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company’s website: www.mankindpharma.com.Other expenses8865800000Remeasurement losses of defined benefit plans-70700000Change in the fair value of equity investments at FVTOCI58100000Share of other comprehensive income/ (loss) of associates and joint ventures0Impairment of investment measured at FVTOCI-62000000-74600000-15200000Exchange differences in translating the financial statements of foreign operations51800000518000000-7600000UnauditedtrueS.R. Batliboi & Co. LLPtrue2027-07-31Bhagi Bhardwaj Gaur & Cotrue2028-05-31